Of the 218 prostate tumors, 34.4% had reduced expression of STRADA, 18.3% exhibited overexpression of TTK, 11.7% either overexpressed or had reduced expression of AKT1, and 15.6% of tumors overexpressed or had amplified AR (Table 2). This evidence concerns the gene AR and prostate neoplasm.